Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Acute myeloid leukemia].

Y Miyazaki1, K Kuriyama

  • 1Department of Hematology, Molecular Medicine Unit, Nagasaki University School of Medicine, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 3, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Prognostic factors in chemotherapies for acute myeloid leukemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2000
Same author

Molecular analysis of latent membrane protein 1 in patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan.

Leukemia & lymphoma·2000
Same author

[Diagnosis and treatment of small peripheral lung cancer].

Nihon rinsho. Japanese journal of clinical medicine·2000
Same author

Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia.

Leukemia research·2000
Same author

Anti-inflammatory action of a novel peptide, SEK-1005, isolated from a Streptomyces.

European journal of pharmacology·2000
Same author

Low-cost soft-copy display accuracy in the detection of pulmonary nodules by single-exposure dual-energy subtraction: comparison with hard-copy viewing.

Journal of digital imaging·2000

Acute myeloid leukemia (AML) treatment involves chemotherapy, stem cell transplants, and differentiation therapy. Further research is needed to confirm if stem cell transplants offer better survival than chemotherapy for AML patients in first remission.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Context:

  • Acute myeloid leukemia (AML) treatment landscape includes combination chemotherapy, hematopoietic stem cell transplantation (HSCT), and differentiation induction therapy.
  • High-dose cytarabine (HDAC) is a standard chemotherapy regimen in the USA and Europe, but its efficacy requires evaluation in Japan.
  • The use of peripheral blood stem cells for HSCT has increased, surpassing bone marrow transplantation, particularly for auto-transplantation.

Purpose:

  • To evaluate the efficacy of high-dose cytarabine (HDAC) in Japan through well-designed clinical trials.
  • To compare the survival benefits of hematopoietic stem cell transplantation (HSCT) versus standard chemotherapy for acute myeloid leukemia (AML) patients in first remission.
  • To explore the role of prognostic factors, including chromosomal abnormalities, in stratifying AML patients for tailored treatment approaches.

Related Experiment Videos

Summary:

  • Current AML treatments comprise chemotherapy, HSCT, and differentiation therapy. High-dose cytarabine (HDAC) is common in Western countries, necessitating Japanese trials.
  • HSCT stem cell sources have expanded, with peripheral blood stem cell transplantation now more frequent than bone marrow transplantation.
  • Differentiation therapy with ATRA has proven successful for acute promyelocytic leukemia (APL), a subtype of AML. Prognostic factors, such as chromosomal abnormalities, are crucial for stratifying AML patients and optimizing treatment response.

Impact:

  • Establishes the need for localized efficacy studies of HDAC in Japan.
  • Highlights the evolving trends in HSCT donor selection.
  • Emphasizes the importance of personalized medicine in AML treatment through risk stratification based on genetic markers and morphology.